[go: up one dir, main page]

CA2190862A1 - Post exposure prevention of hiv - Google Patents

Post exposure prevention of hiv

Info

Publication number
CA2190862A1
CA2190862A1 CA002190862A CA2190862A CA2190862A1 CA 2190862 A1 CA2190862 A1 CA 2190862A1 CA 002190862 A CA002190862 A CA 002190862A CA 2190862 A CA2190862 A CA 2190862A CA 2190862 A1 CA2190862 A1 CA 2190862A1
Authority
CA
Canada
Prior art keywords
administration
hiv
exposure
day
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002190862A
Other languages
English (en)
French (fr)
Inventor
Bo Oberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/251,316 external-priority patent/US5612319A/en
Priority claimed from SE9500348A external-priority patent/SE9500348D0/xx
Application filed by Individual filed Critical Individual
Publication of CA2190862A1 publication Critical patent/CA2190862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002190862A 1994-05-31 1995-05-11 Post exposure prevention of hiv Abandoned CA2190862A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/251,316 US5612319A (en) 1994-05-31 1994-05-31 Postexposure prevention of HIV infection or seroconversion
US08/251,316 1994-05-31
SE9500348-9 1995-02-01
SE9500348A SE9500348D0 (sv) 1995-02-01 1995-02-01 Post exposure prevention of HIV
PCT/SE1995/000524 WO1995032983A1 (en) 1994-05-31 1995-05-11 Post exposure prevention of hiv

Publications (1)

Publication Number Publication Date
CA2190862A1 true CA2190862A1 (en) 1995-12-07

Family

ID=26662215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002190862A Abandoned CA2190862A1 (en) 1994-05-31 1995-05-11 Post exposure prevention of hiv

Country Status (6)

Country Link
EP (1) EP0763048A1 (ja)
JP (1) JPH10501217A (ja)
AU (1) AU697612B2 (ja)
CA (1) CA2190862A1 (ja)
IL (1) IL113846A (ja)
WO (1) WO1995032983A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
AU2005321239B2 (en) 2004-12-30 2009-02-12 Medivir Ab Compounds useful in the treatment of HIV
EP1679076A1 (en) * 2005-01-06 2006-07-12 Medivir Ab Compounds useful in the treatment of HIV
GB0513835D0 (en) * 2005-07-07 2005-08-10 Medivir Ab HIV inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
FI95384C (fi) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Menetelmä 3'-deoksi-3'-substituoitujen metyylinukleosidien valmistamiseksi ja menetelmässä käytettäviä välituotteita
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives

Also Published As

Publication number Publication date
AU697612B2 (en) 1998-10-15
IL113846A0 (en) 1995-08-31
EP0763048A1 (en) 1997-03-19
IL113846A (en) 1999-07-14
WO1995032983A1 (en) 1995-12-07
JPH10501217A (ja) 1998-02-03
AU2633195A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
Munson et al. Antineoplastic activity of cannabinoids
US4879277A (en) Antiviral compositions and methods
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
US5011829A (en) Pharmaceutical composition and method of inhibiting virus
US4880782A (en) Method of treating viral infections in humans and compositions therefor
US4963533A (en) Therapeutic application of dideoxycytidinene
Gochfeld et al. Marine natural products as lead anti-HIV agents
JPS63107936A (ja) 後天性免疫不全症ａｉｄｓに対する医薬
HUT67031A (en) Process for production of preparations for treatment of hiv infection
JPH01501628A (ja) ヒト免疫不全ウイルスの細胞毒性作用に対して有効な酸安定性ジデオキシヌクレオシド
AU652036B2 (en) Sulfated tocopheryl oligosaccharides and antiviral agents including the same as active ingredients
US5180714A (en) Adenosine compounds for the treatment of diseases caused by parasitic protozoa
AU640511B2 (en) Hexa-n-(o-hydroxybenzyl) neomycin b for inhibiting human retroviruses and for the treatment of aids
CA2190862A1 (en) Post exposure prevention of hiv
JPH02204414A (ja) ２′，３′―ジデオキシプリンヌクレオシド／プリンヌクレオシドホスホリラーゼ阻害剤の組合せ療法および組成物
KR960014991B1 (ko) 2',3'-디데옥시시티딘을 극히 저용량으로 함유하는 약제학적 조성물
US5612319A (en) Postexposure prevention of HIV infection or seroconversion
JPH01132526A (ja) 薬剤組成物
US4892876A (en) Method for inhibiting HIV and an pharmaceutical composition therefor
WO2006104292A1 (en) Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
DE60132581T2 (de) Medikament zur behandlung von durch parasitäre protozoen verursachte erkrankungen
US4174407A (en) Antiviral agent
Faraj et al. Selective protection of toxicity of 2′, 3′-dideoxypyrimidine nucleoside analogs by β-d-uridine in human granulocyte-macrophage progenitor cells
CA2180732A1 (en) Anti-hiv drugs
JPH0438727B2 (ja)

Legal Events

Date Code Title Description
FZDE Discontinued